www.novonordisk-us.com Open in urlscan Pro
2a02:26f0:3500:12::1730:17bb  Public Scan

Form analysis
1 forms found in the DOM

POST

<form method="post" class="cmp-form light"><input type="hidden" value="/bin/nncorp/contact-us-email"> <input type="hidden" value=" , , "> <input type="hidden" value="Was this helpful?"> <input type="hidden"
    value="/content/nncorp/us/en/jcr:content/root/container"> <input type="hidden"> <input type="hidden" id="fieldsCrossValidation">
  <div class="tb-Grid tb-Grid--l--24">
    <div class="tb-GridColumn tb-GridColumn--l--20 tb-GridColumn--offset--l--2 title-frame desktop small">
      <h1 class="color-blue h1-s">Was this helpful?</h1>
    </div>
  </div>
  <div class="tb-Grid tb-Grid--l--24 frame-padding has-title small" style="background-color: rgb(226, 240, 250);">
    <div class="tb-GridColumn tb-GridColumn--l--20 tb-GridColumn--offset--l--2 title-frame mobile">
      <div class="tagline color-blue"></div>
      <p class="color-blue h1-s">Was this helpful?</p>
    </div> <input type="hidden" id="validationConfig" value="{&quot;validations&quot;: {
  &quot;Submit&quot;: {
    &quot;type&quot;: &quot;submit&quot;,
    &quot;groupName&quot;: &quot;&quot;
  },
  &quot;Was this page helpful&quot;: {
    &quot;type&quot;: &quot;radio&quot;,
    &quot;groupName&quot;: &quot;&quot;
  }
}, &quot;groups&quot;: &quot;&quot;}">
    <div class="tb-GridColumn tb-GridColumn--l--20 tb-GridColumn--offset--l--2">
      <div class="tb-Grid tb-Grid--l--20 tb-Grid--m--20 tb-Grid--s--20 tb-Grid--xs--20">
        <div class="options tb-GridColumn">
          <fieldset class="cmp-form-options cmp-form-options--radio   form-control">
            <h4 class="cmp-form-options__legend label h4 color-blue m-xxs-bottom"> Let us know! Please rate your experience with this page. <!----></h4>
            <div class="form-control radio-section ">
              <div id="Was this page helpful">
                <div class="position-relative m-xs-bottom"><input type="radio" id="Was this page helpful-0" name="Was this page helpful" value="page-extremely-helpful" class="cmp-form-options__field cmp-form-options__field--radio radio"> <label
                    for="Was this page helpful-0" class="cmp-form-options__field-description label richtext paragraph-s color-blue">Extremely helpful</label></div>
                <div class="position-relative m-xs-bottom"><input type="radio" id="Was this page helpful-1" name="Was this page helpful" value="page-very-helpful" class="cmp-form-options__field cmp-form-options__field--radio radio"> <label
                    for="Was this page helpful-1" class="cmp-form-options__field-description label richtext paragraph-s color-blue">Very helpful</label></div>
                <div class="position-relative m-xs-bottom"><input type="radio" id="Was this page helpful-2" name="Was this page helpful" value="page-somewhat-helpful" class="cmp-form-options__field cmp-form-options__field--radio radio"> <label
                    for="Was this page helpful-2" class="cmp-form-options__field-description label richtext paragraph-s color-blue">Somewhat helpful</label></div>
                <div class="position-relative m-xs-bottom"><input type="radio" id="Was this page helpful-3" name="Was this page helpful" value="page-slightly-helpful" class="cmp-form-options__field cmp-form-options__field--radio radio"> <label
                    for="Was this page helpful-3" class="cmp-form-options__field-description label richtext paragraph-s color-blue">Slightly helpful</label></div>
                <div class="position-relative m-xs-bottom"><input type="radio" id="Was this page helpful-4" name="Was this page helpful" value="page-not-helpful" class="cmp-form-options__field cmp-form-options__field--radio radio"> <label
                    for="Was this page helpful-4" class="cmp-form-options__field-description label richtext paragraph-s color-blue">Not at all helpful</label></div>
              </div> <span class="infotext error-mgs"></span> <!---->
            </div>
            <div class="form-control valid"></div> <span class="infotext color-blue"></span> <input type="hidden" disabled="disabled" value="Was this page helpful" class="track-form-options">
          </fieldset>
        </div>
        <div class="form-button button tb-GridColumn">
          <link rel="stylesheet" href="/etc.clientlibs/nncorp/components/content/form/form-button/clientlibs.min.018dcb5a50472b99b1583d3575ad899c.css" type="text/css">
          <div class="form-button  "><button class="loading-button background-blue button m-s-top button-link-animation button-link-animation-desktop"><span class="text color-white">Submit</span>
              <div class="loading-indicator white">
                <div class="cir cir-1"></div>
                <div class="cir cir-2"></div>
                <div class="cir cir-3"></div>
              </div> <span class="icon icon-right-arrow"></span>
            </button></div>
        </div>
      </div>
    </div>
  </div>
</form>

Text Content

DISCLAIMER STATEMENT


I do not agree
I agree

WARNING!


Ok Cancel


Actor portrayals


AS OF JANUARY 12, 2024


UPDATES ABOUT WEGOVY®

(semaglutide) injection 2.4 mg supply


Actor portrayals



UPDATES ABOUT WEGOVY®

This website will continue to be updated as new information becomes available.

Novo Nordisk continues to see strong interest in our prescription-only medicine
Wegovy® for chronic weight management. Obesity is a serious, chronic, and
misunderstood disease which affects many people, including friends, colleagues,
families, and loved ones. 

We have served over one million U.S. patients with Wegovy® since its approval by
the U.S. Food and Drug Administration in 2021, and more than 600,000 people in
the US are currently taking this medicine to manage their weight.




We are producing and shipping all dose strengths of Wegovy®, running our
manufacturing lines 24 hours a day, seven days a week, manufacturing more
Wegovy® than ever before. However, overall demand continues to outpace our
increasing production of Wegovy®. As a result, we anticipate potential for
ongoing supply disruptions, and some patients may continue having difficulty
filling Wegovy® prescriptions.

We understand how frustrating this is for the communities we serve and recognize
how important it is for people currently using Wegovy® to continue their weight
management journey. We recommend that those who experience challenges filling
their prescriptions speak with their healthcare professional about the best
approach to their treatment, so this does not halt their pursuit of obesity
care.

 * At this time, we do not recommend switching to Saxenda® (liraglutide)
   injection 3 mg as a viable alternate treatment, as we cannot guarantee supply
   to match the continuous rising demand for weight management medications.

There are five dose strengths of Wegovy® – the first three increase in a
stepwise manner leading to the fourth (1.7 mg) and fifth (2.4 mg), maintenance
dose strengths (2.4 mg is recommended per the Prescribing
Information). Following a short-term stock-out of the Wegovy® 1.7 mg dose
strength in the U.S. in mid-December 2023, we resumed shipments in early January
2024.

Click here for an overview of how Wegovy® is made, manufactured and shipped.

We will continue to manage shipments, limiting quantities of the lower dose
strengths (0.25 mg, 0.5 mg, 1 mg) to U.S. wholesalers for distribution to retail
pharmacies, in an effort to support continuity of care for existing patients.

Important Guidance: Filling Your Wegovy® Prescription

 * We recommend that you contact your pharmacy about refills much earlier than
   normal. This applies to online and walk-in pharmacies.
 * Be specific about the dose strength you need as pharmacies are handling all
   five Wegovy® dose strengths and may need to order the prescription you are
   attempting to fill.
 * If you are unable to obtain your specific dose strength, we encourage you to
   try other local pharmacies for availability.

If that is not successful, speak with your healthcare professional about your
treatment plan to determine the best course of action and options available.
Healthcare professionals know their patients' past and current medical history
and are best equipped to make clinical recommendations.


RESPONSIBLE USE OF MEDICINES

We remain committed to driving meaningful change for people living with obesity
and supporting healthcare professionals partnering on their care. As part of
this commitment, we want to ensure that Wegovy® is used properly and responsibly
for the treatment of obesity in consultation with a licensed healthcare
professional. 

At Novo Nordisk, patient safety is paramount. We want to reinforce that Wegovy®
is the only semaglutide-containing Novo Nordisk medication approved by the U.S.
Food and Drug Administration (FDA) for chronic weight management in adults with
obesity or overweight with weight-related medical problems. This
prescription-only medicine is available in a disposable single-use pen and
should be prescribed in direct consultation with, and under the supervision of,
a licensed healthcare professional. We support these medicines being prescribed
to patients who meet the FDA-approved criteria and promote our medicines for
those appropriate patients. Our other semaglutide-based products, Ozempic®
(semaglutide) injection 0.5 mg, 1 mg, or 2 mg and RYBELSUS® (semaglutide)
tablets 7 mg or 14 mg, which are indicated for adults with type 2 diabetes, have
unique safety and efficacy profiles and are not FDA-approved for chronic weight
management. Please see important product information, including the Prescribing
Information for our semaglutide products at semaglutide.com.

Wegovy® is a prescription medication for people living with obesity, a serious
and chronic disease. It has undergone a clinically rigorous FDA regulatory
approval process. Novo Nordisk is the only manufacturer of the FDA-approved
Wegovy®. We cannot validate the safety or effectiveness of products claiming to
contain semaglutide that are not one of our own branded products. Click here to
read more about our commitment to the responsible use of our medicines
containing semaglutide, including our actions to address this important issue.


OUR LONG-TERM COMMITMENT

We continue to build capacity, investing in new contract manufacturing
organizations. In late 2023, we announced an approximately $9.5 billion
investment in expanding and building new production sites, specifically in
Denmark (~$7 billion) and France (~$2.5 billion).

Please know that our commitment to the obesity community is a long-term one. The
demand for Wegovy® reinforces the unmet need and has strengthened our promise to
not only develop innovative medicines but to partner, raise awareness, and
advocate to change how obesity is understood, diagnosed, and treated.

If you are interested in Wegovy®, please discuss with your healthcare
professional (HCP) if it might be right for you.

To see if Wegovy® is covered by your insurance, visit Wegovy.com or contact your
insurance provider.

 


QUESTIONS?

We’ve included some frequently asked questions below and are here to help if you
need additional support at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM
Eastern Time Monday through Friday – and select option 0 for more support and
at Wegovy.com.

Wegovy® is a prescription medicine indicated for adults with obesity (BMI ≥30)
or overweight (excess weight) (BMI ≥27) who also have weight-related medical
problems to help them lose weight and keep it off used with a reduced-calorie
meal plan and increased physical activity.
Wegovy® is also indicated for use in adolescents (≥ 12 years old) with an
initial BMI at or above the 95th percentile for age and sex (based on CDC growth
charts) along with a reduced-calorie meal plan and increased physical activity
to lose weight and keep it off.


IMPORTANT INFORMATION


DON’T HESITATE TO CALL 1-833-4-WEGOVY (1-833-493-4689) AND SELECT OPTION 0 FOR
MORE SUPPORT. YOU ARE OUR NUMBER ONE PRIORITY AND WE’RE HERE TO HELP.


MORE INFORMATION

Prescribing Information Medication Guide for Wegovy®


ANSWERING YOUR QUESTIONS ABOUT WEGOVY® SUPPLY


ARE YOU PRODUCING AND SHIPPING ALL DOSE STRENGTHS, INCLUDING WEGOVY® 1.7 MG?

Following a short-term stock-out of the Wegovy® 1.7 mg dose strength in the U.S.
in mid-December 2023, we resumed shipments in early January 2024. We are
producing and shipping all dose strengths of Wegovy®, running our manufacturing
lines 24 hours a day, seven days a week, manufacturing more Wegovy® than ever
before.




WHY ARE YOU LIMITING QUANTITIES OF THE LOWER DOSE STRENGTHS OF WEGOVY® INTO THE
MARKET?

Limiting quantities of the Wegovy® lower dose strengths to U.S. wholesalers for
distribution to retail pharmacies has been in an effort to support continuity of
care for existing patients. There are multiple factors influencing the flow of
patients through the dose escalation schedule that we cannot directly control.

We have served over one million U.S. patients with Wegovy® since its approval by
the U.S. Food and Drug Administration in 2021, and more than 600,000 people in
the US are currently taking this medicine to manage their weight. This
represents the efforts we have put forward to help as many patients as we can
while continuing to build production capacity, investing in new contract
manufacturing organizations. In late 2023, we announced an approximately $9.5
billion investment in expanding and building new production sites, specifically
in Denmark (~$7 billion) and France (~$2.5 billion).  




HOW LONG WILL THERE BE U.S. WEGOVY® SUPPLY CHALLENGES AND WHAT IS CAUSING THEM?

Given the high continued interest in Wegovy®, we anticipate ongoing supply
disruptions in the U.S., resulting in some patients having difficulty filling
their Wegovy® prescriptions. However, we are running our manufacturing lines 24
hours a day, seven days a week, are actively producing and shipping all dose
strengths of Wegovy® and continue to build production capacity.

Novo Nordisk is serving hundreds of thousands U.S. patients with Wegovy®. We
will continue to manage shipments, limiting quantities of the lower dose
strengths (0.25 mg, 0.5 mg, 1 mg) to wholesalers for distribution to retail
pharmacies, in an effort to support continuity of care for existing patients.

We are actively producing and shipping all dose strengths into the U.S. market
at this time.




I’M CURRENTLY TAKING WEGOVY®. WHAT DOES THIS MEAN FOR ME?

We recommend that you contact your pharmacy much earlier than normal in
anticipation of your next refill. This applies to online and walk-in pharmacies.
If you are unable to obtain your specific dose strength, we encourage you to try
other local pharmacies for availability. If that is not successful, speak with
your healthcare professional about your treatment plan to determine the best
course of action and options available. Healthcare professionals know their
patients’ past and current medical history and are best equipped to make
clinical recommendations.

We also recommend that healthcare professionals take into consideration the
limited supply of Wegovy® as part of their decision-making when initiating new
patients on therapy, recognizing the possibility of disruption in care.




WHAT HAPPENS IF I CANNOT ACCESS MY MEDICATION?

We recommend that you contact your pharmacy much earlier than normal in
anticipation of your next refill. This applies to online and walk-in pharmacies.
If you are unable to obtain your specific dose strength, we encourage you to try
other local pharmacies for availability. Be specific about the dose strength you
have been prescribed as pharmacies are handling all five Wegovy® dose strengths
and may need to order the specific dose you need. If that is not successful,
speak with your healthcare professional about your treatment plan to determine
the best course of action and options available. Healthcare professionals know
their patients' past and current medical history and are best equipped to make
clinical recommendations.




I'M WAITING TO START WEGOVY®. WHEN WILL I BE ABLE TO DO SO?

If you are interested in discussing Wegovy®, a prescription-only medicine, with
your healthcare professional, we recommend you take into consideration the
limited supply of Wegovy® as part of shared decision-making about initiating
therapy, recognizing the possibility of disruption in care. In discussing with
your healthcare professional whether to initiate therapy, keep in mind
that Wegovy® is indicated for chronic weight management and that, as discussed
in the product label, patients who discontinued therapy in a clinical trial
regained some weight after stopping treatment. 




HOW MANY DOSE STRENGTHS OF WEGOVY® ARE THERE?

There are five dose strengths of Wegovy® – the first three increase in a
stepwise manner (starting with 0.25 mg, then 0.5 mg, 1.0 mg) until the fourth
(1.7 mg) and fifth (2.4 mg), maintenance dose strengths (2.4 mg is recommended
per the Prescribing Information).

We recommend that Wegovy® is used in accordance with the FDA-approved
Prescribing Information, including the dose escalation schedule. If you are
having difficulty finding the dose strength you need, please discuss the best
course of action with your healthcare professional.

For more information about the Wegovy® dosing schedule, see the Prescribing
Information and Medication Guide.




WHAT IS NOVO NORDISK DOING TO ENSURE YOU WILL BE ABLE TO MEET CONTINUED DEMAND?

Please know that our commitment to the obesity community is a long-term one and
we are investing significantly in new contract manufacturing organizations to
build capacity to meet this increasing demand. In late 2023, we announced an
approximately $9.5 billion investment in expanding and building new production
sites, specifically in Denmark (~$7 billion) and France (~$2.5 billion).

 




ARE YOU STILL ACTIVELY SHIPPING WEGOVY®?

We are actively producing and shipping all dose strengths into the U.S. market
at this time. Following a short-term stock-out of the Wegovy® 1.7 mg dose
strength in the U.S. in mid-December 2023, we resumed shipments in early January
2024.

We will continue to manage shipments, limiting quantities of the lower dose
strengths (0.25 mg, 0.5 mg, 1 mg) to wholesalers for distribution to retail
pharmacies, in an effort to support continuity of care for existing patients.




WILL CERTAIN REGIONS OF THE U.S. BE MORE AFFECTED THAN OTHERS? RURAL VS CITIES?

We primarily distribute our products to wholesalers, which then supply retail
pharmacies nationwide. Which specific pharmacies or retailers get Wegovy® is
determined by several factors outside of Novo Nordisk control, including
wholesaler distribution and order fulfilment practice.

If you are unable to fill your Wegovy® prescription, you should speak with your
healthcare professional about your treatment plan to determine the best course
of action and options available. Healthcare professionals know your past and
current medical history and are best equipped to make clinical recommendations.

We also recommend that healthcare professionals take into consideration the
limited supply of Wegovy® as part of their decision-making when initiating new
patients on therapy, recognizing the possibility of disruption in care.




IS OZEMPIC® AN ACCEPTABLE SUBSTITUTE FOR WEGOVY®?

Although Wegovy® and Ozempic® both contain semaglutide, they are different
products with different indications, dosages, prescribing information, and
titration schedules, as approved by the FDA. Each medication has a unique safety
and efficacy profile which is detailed in its respective product label. The
products are not interchangeable. We support our medicines being prescribed to
patients who meet the indicated criteria and only promote the FDA-approved
indications of our medicines for appropriate patients. Click here to read more
about our commitment to the responsible use of our medicines.




IS THE “SEMAGLUTIDE/WEGOVY®” BEING OFFERED BY COMPOUNDING PHARMACIES MADE BY
NOVO NORDISK?

We are aware that there are companies claiming to have availability of
Wegovy® or semaglutide. We want consumers and healthcare professionals to know
and be very clear that Novo Nordisk does not sell Wegovy®, or its active
ingredient, semaglutide, for the purposes of compounding with other products.
Novo Nordisk has not conducted studies to evaluate the safety and efficacy of
Wegovy® when compounded with other ingredients. Novo Nordisk is the only company
that has FDA approval to market Wegovy®, and we supply it in a disposable
single-use pen available by prescription only. In addition, the FDA shared
safety information on compounded semaglutide on their website. For more
information, click here: Medications Containing Semaglutide Marketed for Type 2
Diabetes or Weight Loss | FDA.

 




ARE YOU SUPPLYING WEGOVY® TO TELEHEALTH PROVIDERS?

Novo Nordisk is not supplying any telehealth companies with Wegovy®. Any
healthcare professionals prescribing Wegovy® through telehealth companies will
face the same supply challenges as all other healthcare professionals and
patients across the U.S.

We see the growing trend of weight-management telehealth providers and have
heard media reports that some telehealth providers are not providing sufficient
clinical evaluations prior to prescribing semaglutide containing medicines,
including Wegovy® and Ozempic®. Novo Nordisk medicines should only be prescribed
after a close consultation between a licensed healthcare professional and a
patient – considering the medication’s benefits and risks for that individual
patient – and should only be taken under the supervision of a licensed
healthcare professional.




SHOULD I ASK MY HCP ABOUT SAXENDA® (LIRAGLUTIDE) INJECTION 3 MG UNTIL SUPPLY IS
REPLENISHED?

At this time, we do not recommend Saxenda® as a viable alternate treatment, as
we cannot guarantee supply to match the continuous rising demand for
weight-management medications, including Saxenda®. 




I HEAR I CAN GET SEMAGLUTIDE FROM A COMPOUNDING PHARMACY IN A VIAL. SHOULD I DO
THIS?

We are aware that several compounding pharmacies, weight-loss clinics, and
medical spas are claiming to sell or offer compounded semaglutide products. Novo
Nordisk is actively monitoring and taking action against entities that are
engaging in the unlawful sale of compounded semaglutide, disseminating false
advertising, and infringing its trademarks. Novo Nordisk is the only company in
the U.S. with FDA-approved products containing semaglutide, identified under the
trade names Wegovy®, Ozempic®, and RYBELSUS®. No FDA-approved generic versions
of semaglutide currently exist. Compounded products do not have the same safety,
quality, and effectiveness assurances as our FDA-approved drugs, and may expose
patients to health risks.

Novo Nordisk cannot validate the safety or effectiveness of products claiming to
contain semaglutide that are not one of our own branded products. We are
actively working to ensure broad public awareness regarding the difference
between our FDA-approved products and other medicines being labeled as
“semaglutide” and sold by such entities. Further, the practice of selling
compounded semaglutide medicines under Novo Nordisk trade names has the
potential to create consumer confusion and deception, and we will not tolerate
the unauthorized and inappropriate usage of our brand trademarks by third
parties.




ADDITIONAL RESOURCES

Wegovy.com



FROM START TO FINISH: HOW WEGOVY® IS MADE, MANUFACTURED AND SHIPPED





WHAT IS WEGOVY®?

WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine
that may help adults and children aged ≥12 years with obesity (BMI ≥30 for
adults, BMI ≥ 95th percentile for age and sex for children), or some adults with
excess weight (BMI ≥27) (overweight) who also have weight-related medical
problems to help them lose weight and keep it off. Wegovy® should be used with a
reduced calorie meal plan and increased physical activity

 * Wegovy® contains semaglutide and should not be used with other
   semaglutide-containing products or other GLP-1 receptor agonist medicines

 * It is not known if Wegovy® is safe and effective when taken with other
   prescription, over-the counter, or herbal weight loss products

 * It is not known if Wegovy® can be used safely in people with a history of
   pancreatitis

 * It is not known if Wegovy® is safe and effective for use in children under 12
   years of age


IMPORTANT SAFETY INFORMATION


WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT WEGOVY®?

WEGOVY® MAY CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

 * Possible thyroid tumors, including cancer. Tell your healthcare professional
   if you get a lump or swelling in your neck, hoarseness, trouble swallowing,
   or shortness of breath. These may be symptoms of thyroid cancer. In studies
   with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid
   tumors, including thyroid cancer. It is not known if Wegovy® will cause
   thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma
   (MTC) in people
 * Do not use Wegovy® if you or any of your family have ever had a type of
   thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an
   endocrine system condition called Multiple Endocrine Neoplasia syndrome type
   2 (MEN 2)

DO NOT USE WEGOVY® IF:

 * you or any of your family have ever had a type of thyroid cancer called
   medullary thyroid carcinoma (MTC) or if you have an endocrine system
   condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
 * you have had a serious allergic reaction to semaglutide or any of the
   ingredients in Wegovy®

BEFORE USING WEGOVY®, TELL YOUR HEALTHCARE PROFESSIONAL IF YOU HAVE ANY OTHER
MEDICAL CONDITIONS, INCLUDING IF YOU:

 * have or have had problems with your pancreas or kidneys
 * have type 2 diabetes and a history of diabetic retinopathy
 * have or have had depression, suicidal thoughts, or mental health issues
 * are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby.
   You should stop using Wegovy® 2 months before you plan to become pregnant
 * are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes
   into your breast milk

Tell your healthcare professional about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.
Wegovy® may affect the way some medicines work and some medicines may affect the
way Wegovy® works. Tell your healthcare professional if you are taking other
medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows
stomach emptying and can affect medicines that need to pass through the stomach
quickly.

 


WHAT ARE THE POSSIBLE SIDE EFFECTS OF WEGOVY®?

WEGOVY® MAY CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

 * inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call
   your healthcare professional right away if you have severe pain in your
   stomach area (abdomen) that will not go away, with or without vomiting. You
   may feel the pain from your abdomen to your back
 * gallbladder problems. Wegovy® may cause gallbladder problems, including
   gallstones. Some gallstones may need surgery. Call your
   healthcare professional if you have symptoms, such as pain in your upper
   stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay
   colored stools
 * increased risk of low blood sugar (hypoglycemia) in patients with type 2
   diabetes, especially those who also take medicines for type 2 diabetes such
   as sulfonylureas or insulin. This can be both a serious and common side
   effect. Talk to your healthcare professional about how to recognize and treat
   low blood sugar and check your blood sugar before you start and while you
   take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or
   light-headedness, blurred vision, anxiety, irritability or mood changes,
   sweating, slurred speech, hunger, confusion or drowsiness, shakiness,
   weakness, headache, fast heartbeat, or feeling jittery
 * kidney problems (kidney failure). In people who have kidney problems,
   diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration),
   which may cause kidney problems to get worse. It is important for you to
   drink fluids to help reduce your chance of dehydration
 * serious allergic reactions. Stop using Wegovy® and get medical help right
   away, if you have any symptoms of a serious allergic reaction, including
   swelling of your face, lips, tongue, or throat; problems breathing or
   swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid
   heartbeat
 * change in vision in people with type 2 diabetes. Tell your
   healthcare professional if you have changes in vision during treatment with
   Wegovy®
 * increased heart rate. Wegovy® can increase your heart rate while you are at
   rest. Tell your healthcare professional if you feel your heart racing or
   pounding in your chest and it lasts for several minutes
 * depression or thoughts of suicide. You should pay attention to any mental
   changes, especially sudden changes in your mood, behaviors, thoughts, or
   feelings. Call your healthcare professional right away if you have any mental
   changes that are new, worse, or worry you

The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting,
constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset
stomach, dizziness, feeling bloated, belching, gas, stomach flu, heartburn, and
runny nose or sore throat.


WAS THIS HELPFUL?

Was this helpful?

LET US KNOW! PLEASE RATE YOUR EXPERIENCE WITH THIS PAGE.

Extremely helpful
Very helpful
Somewhat helpful
Slightly helpful
Not at all helpful

Submit



SHARE ADDITIONAL COMMENTS WITH US

If you have additional comments or would like to provide feedback on what other
information would be helpful to you, please contact our Customer Care Center at
1-800-727-6500 or submit online. 

© 2023 Novo Nordisk All rights reserved. : US24SEMO00101 January 2024

NOVO NORDISK USA

800 Scudders Mill Road
Plainsboro, NJ 08536
Tel: 1-609-987-5800

CVR-no. 24256790




Novo Nordisk is a registered trademark of Novo Nordisk A/S.

Terms of use

Privacy notice

Cookie policy


change

Novo Nordisk values your privacy and is committed to the transparent use of your
personal information. We use cookies to improve the functionality and
performance of this site, other cookies are used to remember your preferences or
to share relevant content with you. By clicking “Accept All Cookies,” you
consent to our recommended use of cookies in accordance with our Cookie Policy
and Privacy Policy. You can also “Reject All” which leaves only strictly
necessary cookies to enable website functionality. You can always review,
modify, or revoke your consent by clicking “Customize Cookies.”
Accept All Cookies
Reject All
Customize Cookies


COOKIE PREFERENCE CENTER




 * YOUR PRIVACY


 * STRICTLY NECESSARY COOKIES


 * FUNCTIONALITY COOKIES


 * PERFORMANCE COOKIES


 * ADVERTISING COOKIES

YOUR PRIVACY

When you visit any website, it may store or retrieve information on your
browser, often in the form of cookies. This information might be about your
preferences or your device and is mostly used to make the site work as you
expect it to. The information does not identify you, but it can give you a more
personalized web experience. Because we respect your right to privacy, you can
choose whether to allow or disallow certain categories of cookies on Novo
Nordisk websites. Click on the different category headings to the left to find
out more about these cookies do and change which cookies categories you allow.
However, understand that blocking some types of cookies may impact your
experience of the site and the services we are able to offer.
More information

STRICTLY NECESSARY COOKIES

Always Active

These cookies are required for the operation of our website and cannot be
switched off without impairing the functionality of the site. Strictly necessary
cookies are set to respond to actions you take, including navigating our site
and using its basics features. These cookies do not store any Personal
Information.

FUNCTIONALITY COOKIES

Functionality Cookies Active


Allow our websites to remember your user name, language preference, or
geographic region. This information is used to provide a personalised experience
and to make the website easier to use. If you don’t allow these cookies, then
some or all features may not function.

PERFORMANCE COOKIES

Performance Cookies Active


Collect information about your use of our website, e.g. page visits or error
messages. This information is aggregated and anonymized and used to improve our
website. If you don’t allow these cookies, we won’t know when you have visited
our website and won’t be able to monitor its performance.

ADVERTISING COOKIES

Advertising Cookies Active


Allow us to display advertising we think is relevant to you. We build profiles
based on your browsing history, which we share with our advertising partners to
show you relevant advertisements on other sites. If you don’t allow these
cookies you will still receive advertising, but it will be less relevant.

Back Button


COOKIE LIST

Filter Button
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Clear
checkbox label label
Apply Cancel
Confirm My Choices
Reject All Allow All